Use in Specific Populations
In this section, you can review results from clinical trials in which CRESTOR®
(rosuvastatin calcium) was used as an adjunct to diet in African-American and Hispanic-American patients.
Use in African-American Patients
-
LDL-C reductions vs atorvastatin in African-American adults with hyperlipidemia or mixed dyslipidemia36
-
-
LDL-C goal attainment (LDL-C <100 mg/dL) vs atorvastatin in high-risk African-American adults with hyperlipidemia or mixed dyslipidemia36,37
-
-
HDL-C increases vs atorvastatin in African-American adults with hyperlipidemia or mixed dyslipidemia36
-
Use in Hispanic-American Patients
-
LDL-C reductions vs atorvastatin in moderate-risk and high-risk Hispanic-American adults38
-
-
LDL-C goal attainment (LDL-C <100 mg/dL) in moderate-risk and high-risk Hispanic-American adults39,40
-
As an adjunct to diet,
LDL-C reductions vs atorvastatin in African-American adults with hyperlipidemia or mixed dyslipidemia36
ARIES was a 6-week, randomized, open-label, comparative,
multicenter study. Following a 6-week dietary lead-in period,
self-described African-American adults with hyperlipidemia or mixed dyslipidemia
were randomized to receive either CRESTOR
10 mg or 20 mg or atorvastatin 10 mg or 20 mg for 6 weeks.
Primary end point was change from baseline in LDL-C at week 6.
Secondary end points at week 6 included achievement of NCEP ATP
III LDL-C goals and percentage change in HDL-C and other lipid
parameters.36
As an adjunct to diet,
LDL-C goal attainment (LDL-C <100 mg/dL) vs atorvastatin in high-risk African-American adults with hyperlipidemia or mixed dyslipidemia36,37
ARIES was a 6-week, randomized, open-label, comparative,
multicenter study. Following a 6-week dietary lead-in period,
self-described African-American adults with hyperlipidemia or mixed dyslipidemia
were randomized to receive either CRESTOR
10 mg or 20 mg or atorvastatin 10 mg or 20 mg for 6 weeks.
Primary end point was change from baseline in LDL-C at week 6.
Secondary end points at week 6 included achievement of NCEP ATP
III LDL-C goals and percentage change in HDL-C and other lipid parameters.36
As an adjunct to diet,
HDL-C increases vs atorvastatin in African-American adults with hyperlipidemia or mixed dyslipidemia36
ARIES was a 6-week, randomized, open-label, comparative,
multicenter study. Following a 6-week dietary lead-in period,
self-described African-American adults with hyperlipidemia or mixed dyslipidemia
were randomized to receive either CRESTOR
10 mg or 20 mg or atorvastatin 10 mg or 20 mg for 6 weeks.
Primary end point was change from baseline in LDL-C at week 6.
Secondary end points at week 6 included achievement of NCEP ATP
III LDL-C goals and percentage change in HDL-C and other lipid parameters.36
As an adjunct to diet,
LDL-C reductions vs atorvastatin in moderate-risk and high-risk Hispanic-American adults38
STARSHIP was a 6-week, randomized, open-label, comparative,
multicenter study. Following a 6-week dietary lead-in period,
patients were randomized to 1 of 4 arms: CRESTOR 10 mg or 20 mg
or atorvastatin 10 mg or 20 mg once daily for 6 weeks. Inclusion
criteria for randomization: self-described Hispanic-American adults
(aged ≥18 years) with 10-year CHD risk ≥10%, or CHD or CHD
risk equivalent; LDL-C levels ≥130 mg/dL and ≤300 mg/dL; and
triglyceride levels <400 mg/dL.38
As an adjunct to diet,
LDL-C goal attainment (LDL-C <100 mg/dL) in moderate-risk and high-risk Hispanic-American adults*39,40
This retrospective analysis of goal attainment was adapted from the STARSHIP trial.40
STARSHIP was a 6-week, randomized, open-label, comparative,
multicenter study.38 Following a 6-week dietary lead-in period,
patients were randomized to 1 of 4 arms: CRESTOR 10 mg or 20 mg
or atorvastatin 10 mg or 20 mg once daily for 6 weeks.38
Inclusion criteria for randomization: self-described Hispanic-American
adults (aged ≥18 years) with 10-year CHD risk ≥10%, or CHD or
CHD risk equivalent; LDL-C levels ≥130 mg/dL and ≤300 mg/dL;
and triglycerides <400 mg/dL.38